You are here: Industry Insights > Transgene

News List

First person enrolled in Phase I oncolytic virus trial europeanpharmaceuticalreview
March 04, 2021
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
Vaxxel buys Transgene’s cell line to develop new vaccines pharmaceutical-technology
May 05, 2020
French vaccines startup Vaxxel has acquired Transgene’s DuckCelt T17 cell line to develop industrial-scale vaccines against respiratory viruses.
AZ, Transgene to collaborate on immunotherapies pharmatimes
May 10, 2019
AZ, Transgene to collaborate on immunotherapies
AstraZeneca and Transgene to develop cancer drug candidates pharmaceutical-technology
May 05, 2019
AstraZeneca has signed an agreement with French biotech company Transgene to develop cancer drug candidates using genetically engineered vaccinia viruses.
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors pharmafocusasia
March 27, 2019
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibod
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activi biospace
March 16, 2018
TRANSGENE will be presenting a poster with new and encouraging preclinical data on a novel viral vector at the AACR Annual Meeting 2018, Chicago, IL, USA, April 14 – 18.
First Chronic Hepatitis B Patient Dosed in China in a Phase I Trial of T101 (Transgene’s TG1050 Tech biospace
January 18, 2018
TRANSGENE SA (Paris: TNG) announced that the first patient conducted a phase 1 clinical trial in China to evaluate the efficacy of the T101 vaccine in immunotherapy of chronic hepatitis B virus (HBV) infection.
Transgene Announces Financial Calendar for 2018 biospace
December 26, 2017
TRANSGENE S.A. (Paris:TNG) today announced its financial reporting dates for 2018